Author

Adi Naamti

Eleven Therapeutics (UK) Ltd. (United Kingdom)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Ahmet Can BerkyurekiD· 1 shared Christopher Cole HoneycuttiD· 1 shared Daniel C. DouekiD· 1 shared Dario BressaniD· 1 shared Giorgia BattistoniiD· 1 shared Gregory J. HannoniD· 1 shared Ian GoodfellowiD· 1 shared Ilaria Falciatori· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenomics

Ahmet Can BerkyurekORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Genome wide screen of RNAi molecules against SARS-CoV-2 creates a broadly potent prophylaxis

Ohad Yogev, Omer Weissbrod, Giorgia Battistoni, Dario Bressan, Adi Naamti, Ilaria Falciatori, Ahmet Can Berkyurek, Roni Rasnic, Myra D.T. Hosmillo, Shaul Ilan, Iris Grossman, Lauren McCormick, Christopher Cole Honeycutt, Timothy S. Johnston, Matthew Gagné, , Yaniv Erlich

The paper identifies potent siRNAs against SARS-CoV-2 through RNAi screening, validates their efficacy against variants, and demonstrates their prophylactic potential in a hamster model.

bioRxiv · Apr 12, 2022 · PreprintGenomics